Related Articles
Efficacy and safety of humanized CD19 CAR‑T as a salvage therapy for recurrent CNSL of B‑ALL following murine CD19 CAR‑T cell therapy
A phase I study of CAR‑T bridging HSCT in patients with acute CD19<sup>+</sup> relapse/refractory B‑cell leukemia
CAR T cell therapy: A new era for cancer treatment (Review)
Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)
CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated